Abstract
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which primarily affects the respiratory tract. Combinations of drugs are used for therapeutic synergism and to prevent the emergence of drug resistant strains, but even first- or secondchoice drugs present some disadvantages, such as significant side effects and the need for long duration of treatments. Thus, new strategies for TB control and treatment are highly demanded. In this context, protein tyrosine phosphatases (PtpA and PtpB) are secreted by Mtb within the host macrophage and they have been shown to contribute to Mtb pathogenicity. The understanding of the role of these PTPs has led to interesting anti-TB drugs discovery. Here, we review the current knowledge on these two proteins as targets for novel anti-TB therapies, with particular emphasis on their mechanism of action and current advancements in developing small molecule inhibitors from natural sources.
Keywords: Tuberculosis, Mycobacterium tuberculosis, tyrosine phosphatases, PtpA, PtpB.
Current Pharmaceutical Design
Title:Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs
Volume: 22 Issue: 12
Author(s): Alessandra Mascarello, Louise Domeneghini Chiaradia-Delatorre, Mattia Mori, Hernán Terenzi and Bruno Botta
Affiliation:
Keywords: Tuberculosis, Mycobacterium tuberculosis, tyrosine phosphatases, PtpA, PtpB.
Abstract: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which primarily affects the respiratory tract. Combinations of drugs are used for therapeutic synergism and to prevent the emergence of drug resistant strains, but even first- or secondchoice drugs present some disadvantages, such as significant side effects and the need for long duration of treatments. Thus, new strategies for TB control and treatment are highly demanded. In this context, protein tyrosine phosphatases (PtpA and PtpB) are secreted by Mtb within the host macrophage and they have been shown to contribute to Mtb pathogenicity. The understanding of the role of these PTPs has led to interesting anti-TB drugs discovery. Here, we review the current knowledge on these two proteins as targets for novel anti-TB therapies, with particular emphasis on their mechanism of action and current advancements in developing small molecule inhibitors from natural sources.
Export Options
About this article
Cite this article as:
Mascarello Alessandra, Chiaradia-Delatorre Domeneghini Louise, Mori Mattia, Terenzi Hernán and Botta Bruno, Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs, Current Pharmaceutical Design 2016; 22 (12) . https://dx.doi.org/10.2174/1381612822666160112130539
DOI https://dx.doi.org/10.2174/1381612822666160112130539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficient Antibacterial Agents: A Review of the Synthesis, Biological Evaluation and Mechanism of Pleuromutilin Derivatives
Current Topics in Medicinal Chemistry Epoxide Hydrolases and their Application in Organic Synthesis
Current Organic Chemistry Targeting Intracellular Targets
Current Drug Delivery Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Microbial Metabolomics
Current Genomics Inhibitors of Mycothiol-S-Conjugate Amidase and Related Genes
Current Medicinal Chemistry - Anti-Infective Agents Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Bacterial Lipoprotein Biosynthetic Pathway as a Potential Target for Structure-based Design of Antibacterial Agents
Current Medicinal Chemistry Vitamin D Deficiency in Tuberculosis and Diabetes Mellitus - A Cluster Analysis
Current Respiratory Medicine Reviews State of the Art Review and Report of New Tool for Drug Discovery
Current Topics in Medicinal Chemistry Graphical Abstracts:
Letters in Drug Design & Discovery Molecular Topology and Other Promiscuity Determinants as Predictors of Therapeutic Class - A Theoretical Framework to Guide Drug Repositioning?
Current Topics in Medicinal Chemistry Current Research Issues in the Pharmacokinetics of Antiretroviral Drugs in Children
Current Pediatric Reviews Design, Synthesis and Anti-tuberculosis Activity of Hydrazones and N-acylhydrazones Containing Vitamin B6 and Different Heteroaromatic Nucleus
Letters in Drug Design & Discovery An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis
Current Medicinal Chemistry Defining ‘Satisfactory Response’ to Therapy in Abdominal Tuberculosis: A Work in Progress
Infectious Disorders - Drug Targets Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets Reaction of Some Substituted 3-Aryl-4-formylsydnones with Tetra-Oacetyl- β-D-galactopyranosyl)thiosemicarbazide
Letters in Organic Chemistry Mycobacterium tuberculosis and Dendritic Cells: Whos Manipulating Whom?
Current Immunology Reviews (Discontinued) Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety